Liposomal siRNA nanocarriers for cancer therapy

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Therapeutics

Background:

• Small interfering RNAs (siRNA) are a promising therapeutic class for gene silencing in diseases like cancer.
• Current siRNA delivery faces challenges including degradation, poor cellular uptake, and rapid clearance, limiting clinical use.
• Lipid-based nanoparticles are explored for siRNA delivery, but cationic liposomes are toxic and anionic liposomes are cleared quickly.

Purpose of the Study:

• To develop and evaluate safe and effective neutral lipid-based nanoliposomes for systemic siRNA delivery in cancer therapy.
• To demonstrate robust gene silencing and significant antitumor efficacy of the developed nanoliposomes in preclinical cancer models.

Main Methods:

• Development of neutral lipid-based nanoliposomes for siRNA encapsulation and delivery.
• Systemic (intravenous) administration of nanoliposomes in orthotopic human cancer models in animals.
• Assessment of gene silencing efficacy and antitumor activity in various tumor models.

Main Results:

• Neutral lipid-based nanoliposomes demonstrated robust gene silencing in tumors following systemic administration.
• The developed delivery system exhibited remarkable antitumor efficacy across diverse orthotopic human cancer models.
• This approach overcomes the toxicity and clearance issues associated with cationic and anionic liposomes.

Conclusions:

• Neutral lipid-based nanoliposomes represent a highly safe and effective platform for siRNA-based cancer nanotherapeutics.
• This technology holds significant potential for clinical applications in treating human cancers through targeted gene silencing.